Article
TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3.
Antimicrobial agents and chemotherapy - 1 Dec 2001
Neuwirth C, Madec S, Siebor E, Pechinot A, Duez J M, Pruneaux M, Fouchereau-Peron M, Kazmierczak A, Labia R
Abstract excerpt
TEM-89 (CMT-3) is the first complex mutant beta-lactamase produced by a clinical strain of Proteus mirabilis (strain Pm 631). This new enzyme, which has a pI of 6.28, is derived from TEM-3 and has a single amino acid substitution also encountered in TEM-59 (inhibitor-resistant TEM beta-lactamase IRT-17): Ser-130 to Gly. TEM-89 hydrolyzed penicillins to the same extent that TEM-3 did but lost almost all hydrolytic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
